Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 3.69 USD 9.5% Market Closed
Market Cap: 467.4m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CTKB stock under the Base Case scenario is 7.51 USD. Compared to the current market price of 3.69 USD, Cytek Biosciences Inc is Undervalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTKB Relative Value
Base Case
7.51 USD
Undervaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.4
P/S
P/S
Price to Sales
2.4
vs History
90
vs Industry
59
Median 3Y
5.3
Median 5Y
6.1
Industry
4
Forward
2.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
-84
Median 5Y
-124.9
Industry
31.5
Forward
-16.8
More Details
22.1
P/OCF
P/OCF
Price to OCF
22.1
vs History
64
vs Industry
25
Median 3Y
21.6
Median 5Y
26.2
Industry
19.6
More Details
24.9
P/FCFE
P/FCFE
Price to FCFE
24.9
vs History
40
vs Industry
24
Median 3Y
-75.5
Median 5Y
-73.8
Industry
32.5
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
94
vs Industry
64
Median 3Y
2.3
Median 5Y
2.8
Industry
2.7
More Details
1
EV/S
EV/S
Enterprise Value to Sales
1
vs History
90
vs Industry
76
Median 3Y
3.7
Median 5Y
4.6
Industry
3.8
Forward
1
More Details
1.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.9
vs History
90
vs Industry
77
Median 3Y
6.5
Median 5Y
7.6
Industry
8.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
0
Median 3Y
-27.4
Median 5Y
-14.8
Industry
17.6
Forward
12.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
2
Median 3Y
-22
Median 5Y
-18.7
Industry
23.9
Forward
-8
More Details
9.7
EV/OCF
EV/OCF
Enterprise Value to OCF
9.7
vs History
64
vs Industry
42
Median 3Y
11.1
Median 5Y
16.5
Industry
18.2
More Details
11.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
11.9
vs History
52
vs Industry
32
Median 3Y
5.1
Median 5Y
11.2
Industry
23.3
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
94
vs Industry
62
Median 3Y
3
Median 5Y
4
Industry
2.4
More Details

Multiples Across Competitors

CTKB Competitors Multiples
Cytek Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cytek Biosciences Inc
NASDAQ:CTKB
470.8m USD 2.4 -41.8 -15.7 -8.3
US
PerkinElmer Inc
LSE:0KHE
1.1T USD 413.2 3 992.8 1 399.8 2 855.1
US
Thermo Fisher Scientific Inc
NYSE:TMO
180.6B USD 4.2 27.4 21.1 26.4
US
Danaher Corp
NYSE:DHR
147.1B USD 6.1 43.1 22.5 33.9
KR
Samsung Biologics Co Ltd
KRX:207940
71.2T KRW 14.5 55.6 32.3 44.9
CH
Lonza Group AG
SIX:LONN
39.6B CHF 6 62.3 22.8 35.6
US
IQVIA Holdings Inc
NYSE:IQV
34.7B USD 2.2 26 13.6 20.2
US
Agilent Technologies Inc
NYSE:A
34.1B USD 5.1 29.3 19.8 23.4
CN
WuXi AppTec Co Ltd
SSE:603259
256.7B CNY 6.3 23 22.4 22.4
US
Mettler-Toledo International Inc
NYSE:MTD
26.3B USD 6.9 30.9 22.9 25.4
IN
Divi's Laboratories Ltd
NSE:DIVISLAB
1.8T INR 19.1 79.5 57.7 66.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cytek Biosciences Inc
NASDAQ:CTKB
Average EV/EBITDA: 163.5
Negative Multiple: -15.7 		N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
1 399.8
7%
200
US
Thermo Fisher Scientific Inc
NYSE:TMO
21.1
6%
3.5
US
Danaher Corp
NYSE:DHR
22.5
7%
3.2
KR
Samsung Biologics Co Ltd
KRX:207940
32.3
17%
1.9
CH
Lonza Group AG
SIX:LONN
22.8
18%
1.3
US
IQVIA Holdings Inc
NYSE:IQV
13.6
9%
1.5
US
Agilent Technologies Inc
NYSE:A
19.8
10%
2
CN
WuXi AppTec Co Ltd
SSE:603259
22.4
24%
0.9
US
Mettler-Toledo International Inc
NYSE:MTD
22.9
4%
5.7
IN
Divi's Laboratories Ltd
NSE:DIVISLAB
57.7
24%
2.4

See Also

Summary
CTKB intrinsic value, competitors valuation, and company profile.
DCF Valuation
CTKB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CTKB stock valuation using valuation multiples.
Wall Street Estimates
CTKB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CTKB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.